Journal
CANCER
Volume 116, Issue 5, Pages 1165-1176Publisher
WILEY
DOI: 10.1002/cncr.24862
Keywords
acute lymphoblastic leukemia; cytogenetic and molecular abnormalities; Philadelphia chromosome; targeted therapy
Categories
Funding
- National Institutes of Health [CA21765]
- American Lebanese Syrian Associated Charities
- NATIONAL CANCER INSTITUTE [P30CA016672, P30CA021765] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued. Although ALL is a success story in pediatric oncology, results in adults lag behind those in children. An expansion of new drugs, more reliable immunologic and molecular techniques for the assessment of minimal residual disease, and efforts at more precise risk stratification are generating new aspects of adult ALL therapy. For this review, the authors summarized pertinent and recent literature on ALL biology and therapy, and they discuss current strategies and potential implications of novel approaches to the management of adult ALL. Cancer 2010;116:1165-76. (C) 2070 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available